1. Home
  2. FATE vs LARK Comparison

FATE vs LARK Comparison

Compare FATE & LARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FATE
  • LARK
  • Stock Information
  • Founded
  • FATE 2007
  • LARK 1885
  • Country
  • FATE United States
  • LARK United States
  • Employees
  • FATE N/A
  • LARK N/A
  • Industry
  • FATE Biotechnology: Biological Products (No Diagnostic Substances)
  • LARK Major Banks
  • Sector
  • FATE Health Care
  • LARK Finance
  • Exchange
  • FATE Nasdaq
  • LARK Nasdaq
  • Market Cap
  • FATE 125.7M
  • LARK 142.3M
  • IPO Year
  • FATE 2013
  • LARK N/A
  • Fundamental
  • Price
  • FATE $1.15
  • LARK $26.83
  • Analyst Decision
  • FATE Hold
  • LARK
  • Analyst Count
  • FATE 7
  • LARK 0
  • Target Price
  • FATE $3.58
  • LARK N/A
  • AVG Volume (30 Days)
  • FATE 1.5M
  • LARK 7.3K
  • Earning Date
  • FATE 08-12-2025
  • LARK 07-24-2025
  • Dividend Yield
  • FATE N/A
  • LARK 3.26%
  • EPS Growth
  • FATE N/A
  • LARK 43.23
  • EPS
  • FATE N/A
  • LARK 2.81
  • Revenue
  • FATE $8,470,000.00
  • LARK $62,413,000.00
  • Revenue This Year
  • FATE N/A
  • LARK N/A
  • Revenue Next Year
  • FATE N/A
  • LARK N/A
  • P/E Ratio
  • FATE N/A
  • LARK $9.55
  • Revenue Growth
  • FATE N/A
  • LARK 11.63
  • 52 Week Low
  • FATE $0.66
  • LARK $18.81
  • 52 Week High
  • FATE $4.20
  • LARK $31.04
  • Technical
  • Relative Strength Index (RSI)
  • FATE 53.09
  • LARK 57.33
  • Support Level
  • FATE $1.06
  • LARK $25.75
  • Resistance Level
  • FATE $1.18
  • LARK $26.86
  • Average True Range (ATR)
  • FATE 0.09
  • LARK 0.73
  • MACD
  • FATE 0.02
  • LARK 0.18
  • Stochastic Oscillator
  • FATE 72.73
  • LARK 88.23

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.

Share on Social Networks: